SOAM
REGN icon

SBI Okasan Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SBI Okasan Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Hold
1,200
– – 0.02% 168
2026
Q1 		$899K Sell
1,200
-300
-20% -$230K 0.04% 121
2025
Q4 		$1.17M Buy
+1,500
New +$1.02M 0.06% 102

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SBI Okasan Asset Management's REGN Position: Q2 2026 in Review

SBI Okasan Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 1,200 shares worth $758K. The position accounts for 0.02% of the portfolio, ranked #168.

SBI Okasan Asset Management first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.17M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • SBI Okasan Asset Management held 1,200 shares of Regeneron Pharmaceuticals worth $758K as of Q2 2026.
  • SBI Okasan Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.02% of SBI Okasan Asset Management's portfolio in Q2 2026, its #168 holding.
  • SBI Okasan Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • SBI Okasan Asset Management's Regeneron Pharmaceuticals position peaked at $1.17M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.